BDBM295665 (S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepin-9- yl)amino)propanamide::US10112932, Compound 101::US10851091, Compound 101

SMILES C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O

InChI Key InChIKey=SGEUNORSOZVTOL-UHFFFAOYSA-N

Data  12 KI  6 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 19 hits for monomerid = 295665   

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataEC50:  19nMAssay Description:Inhibition of PI3Kalpha H1047R mutant in human HCC1954 cells assessed as reduction in PRAS40 phosphorylation after 24 hrs by electrochemiluminescent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 1A2(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 2C19(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 2C8(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 2C9(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 2D6(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetCytochrome P450 3A4(Human)
Genentech

Curated by ChEMBL
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  0.0340nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  0.0340nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  0.0340nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  12nMAssay Description:Inhibition of PI3Kdelta (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  12.2nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  12.2nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  18nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  18.2nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  18.2nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  99.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  99.7nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  100nMAssay Description:Inhibition of PI3Kbeta (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed